Serum Response Factor Expression, Microvascular Density, and Postoperative Recurrence in Glioblastoma.

IF 2.8 4区医学 Q3 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

OncoTargets and therapy Pub Date : 2025-09-19 eCollection Date: 2025-01-01 DOI:10.2147/OTT.S546017

Bo Tan, Shuangyin He, Tao Chen, Peng Song, Yaohui Huang, Xiaohong Yin

{"title":"Serum Response Factor Expression, Microvascular Density, and Postoperative Recurrence in Glioblastoma.","authors":"Bo Tan, Shuangyin He, Tao Chen, Peng Song, Yaohui Huang, Xiaohong Yin","doi":"10.2147/OTT.S546017","DOIUrl":null,"url":null,"abstract":"Objective: To investigate the association between serum response factor (SRF) expression, tumour microvascular density (MVD), and postoperative recurrence in glioblastoma.Methods: This retrospective study analysed 92 patients with histologically confirmed glioblastoma treated between July 2021 and July 2023. Tumour and adjacent normal brain tissues were collected during surgery for immunohistochemical detection of SRF and CD105. MVD was determined by counting CD105-positive microvessels in the most vascularised tumour regions. Spearman correlation assessed the association between SRF and MVD. All patients underwent maximal surgical resection and were followed for 1 year. Recurrence was defined by MRI. Multivariate logistic regression identified independent predictors of recurrence.Results: SRF-positive tumours were significantly more frequent than in adjacent normal brain tissue (56.5% vs 2.2%, P<0.001) and had higher MVD (86.79 ± 14.12 vs 70.58 ± 8.77 vessels/field, P<0.05). SRF expression correlated positively with MVD (r = 0.749, P<0.05). At 1 year, 24 patients (26.1%) recurred. Compared with non-recurrent cases, the recurrence group had higher rates of SRF positivity, tumour size ≥5 cm, poor differentiation, high grade, and incomplete resection (all P<0.05). Multivariate analysis identified SRF positivity, tumour size ≥5 cm, poor differentiation, high grade, and incomplete resection as independent recurrence predictors.Conclusion: SRF overexpression in glioblastoma is associated with increased angiogenesis and higher recurrence risk. SRF may promote tumour proliferation, differentiation, and migration, and serve as a prognostic biomarker and potential therapeutic target.","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":"18 ","pages":"1043-1052"},"PeriodicalIF":2.8000,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12456318/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"OncoTargets and therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/OTT.S546017","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To investigate the association between serum response factor (SRF) expression, tumour microvascular density (MVD), and postoperative recurrence in glioblastoma.

Methods: This retrospective study analysed 92 patients with histologically confirmed glioblastoma treated between July 2021 and July 2023. Tumour and adjacent normal brain tissues were collected during surgery for immunohistochemical detection of SRF and CD105. MVD was determined by counting CD105-positive microvessels in the most vascularised tumour regions. Spearman correlation assessed the association between SRF and MVD. All patients underwent maximal surgical resection and were followed for 1 year. Recurrence was defined by MRI. Multivariate logistic regression identified independent predictors of recurrence.

Results: SRF-positive tumours were significantly more frequent than in adjacent normal brain tissue (56.5% vs 2.2%, P<0.001) and had higher MVD (86.79 ± 14.12 vs 70.58 ± 8.77 vessels/field, P<0.05). SRF expression correlated positively with MVD (r = 0.749, P<0.05). At 1 year, 24 patients (26.1%) recurred. Compared with non-recurrent cases, the recurrence group had higher rates of SRF positivity, tumour size ≥5 cm, poor differentiation, high grade, and incomplete resection (all P<0.05). Multivariate analysis identified SRF positivity, tumour size ≥5 cm, poor differentiation, high grade, and incomplete resection as independent recurrence predictors.

Conclusion: SRF overexpression in glioblastoma is associated with increased angiogenesis and higher recurrence risk. SRF may promote tumour proliferation, differentiation, and migration, and serve as a prognostic biomarker and potential therapeutic target.

Abstract Image

查看原文本刊更多论文

胶质母细胞瘤的血清反应因子表达、微血管密度与术后复发。

目的：探讨血清反应因子（SRF）表达、肿瘤微血管密度（MVD）与胶质母细胞瘤术后复发的关系。方法：本回顾性研究分析了2021年7月至2023年7月期间接受组织学证实的92例胶质母细胞瘤患者。术中采集肿瘤及邻近正常脑组织进行SRF和CD105免疫组化检测。MVD是通过计数大多数血管化肿瘤区域的cd105阳性微血管来确定的。Spearman相关性评估SRF和MVD之间的关系。所有患者均行最大手术切除，随访1年。通过MRI确定复发。多因素logistic回归确定了独立的复发预测因子。结果：SRF阳性肿瘤的发生率明显高于相邻正常脑组织（56.5% vs 2.2%）。结论：SRF在胶质母细胞瘤中过表达与血管生成增加和复发风险升高有关。SRF可能促进肿瘤增殖、分化和迁移，并可作为预后生物标志物和潜在的治疗靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

OncoTargets and therapy BIOTECHNOLOGY & APPLIED MICROBIOLOGY-ONCOLOGY

CiteScore

9.70

自引率

0.00%

发文量

221

审稿时长

1 months

期刊介绍： OncoTargets and Therapy is an international, peer-reviewed journal focusing on molecular aspects of cancer research, that is, the molecular diagnosis of and targeted molecular or precision therapy for all types of cancer. The journal is characterized by the rapid reporting of high-quality original research, basic science, reviews and evaluations, expert opinion and commentary that shed novel insight on a cancer or cancer subtype. Specific topics covered by the journal include: -Novel therapeutic targets and innovative agents -Novel therapeutic regimens for improved benefit and/or decreased side effects -Early stage clinical trials Further considerations when submitting to OncoTargets and Therapy: -Studies containing in vivo animal model data will be considered favorably. -Tissue microarray analyses will not be considered except in cases where they are supported by comprehensive biological studies involving multiple cell lines. -Biomarker association studies will be considered only when validated by comprehensive in vitro data and analysis of human tissue samples. -Studies utilizing publicly available data (e.g. GWAS/TCGA/GEO etc.) should add to the body of knowledge about a specific disease or relevant phenotype and must be validated using the authors’ own data through replication in an independent sample set and functional follow-up. -Bioinformatics studies must be validated using the authors’ own data through replication in an independent sample set and functional follow-up. -Single nucleotide polymorphism (SNP) studies will not be considered.